Emily Cheves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily Cheves has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Holly Landrum Peay
RTI International, Durham North Carolina, Durham, USA
4 shared publications - Anne C. Wheeler
RTI International, Research Triangle Park, USA
3 shared publications - Heidi Cope
RTI International, Genomics and Translational Research Center, Research Triangle Park, 3040 East Cornwallis Road, Durham, NC 27713, USA
3 shared publications - Samantha Scott
RTI International, Genomics and Translational Research Center, Research Triangle Park, 3040 East Cornwallis Road, Durham, NC 27713, USA
3 shared publications - Sara Morris Andrews
RTI International Research Triangle Park North Carolina USA
3 shared publications - Ana N. Forsythe
RTI International, Durham, North Carolina
2 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 23
A Systematic Process to Accurately Link Large-Scale Research Consents to State Public Health Newborn Screening Samples
Research programs can interface with public health programs to generate innovation, yet it is critical to ensure processes that support research activities without infringing on protected data. Genomic newborn screening (gNBS) research programs require reliable methods to link parental consents to the correct newborn screening (NBS) specimen. Early Check is a gNBS research program in North Carolina that uses the residual dried bloodspot (DBS) samples stored at the North Carolina State Laboratory of Public Health (NCSLPH) to screen babies for serious health conditions. Early Check created a systematic approach to match research consents with NBS DBS samples utilizing a fuzzy matching algorithm and manual review of prospective matches utilizing a decision tree. Between 28 September 2023, and 10 June 2025, Early Check received parental consents for 4279 newborns. Of those, 614 (14%) had discrepancies that required further review. More than half of these (349, 57%) required outreach to the consenting parent to resolve differences in information such as name, infant sex, or contact details. The use of probabilistic matching, a decision tree, and structured staff review provides a feasible approach for accurately identifying samples from consented NBS participants.
- 14 April 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (2) , 23
Open AccessA Systematic Process to Accurately Link Large-Scale Research Consents to State Public Health Newborn Screening Samples
Research programs can interface with public health programs to generate innovation, yet it is critical to ensure processes that support research activities without infringing on protected data. Genomic newborn screening (gNBS) research programs require reliable methods to link parental consents to the correct newborn screening (NBS) specimen. Early Check is a gNBS research program in North Carolina that uses the residual dried bloodspot (DBS) samples stored at the North Carolina State Laboratory of Public Health (NCSLPH) to screen babies for serious health conditions. Early Check created a systematic approach to match research consents with NBS DBS samples utilizing a fuzzy matching algorithm and manual review of prospective matches utilizing a decision tree. Between 28 September 2023, and 10 June 2025, Early Check received parental consents for 4279 newborns. Of those, 614 (14%) had discrepancies that required further review. More than half of these (349, 57%) required outreach to the consenting parent to resolve differences in information such as name, infant sex, or contact details. The use of probabilistic matching, a decision tree, and structured staff review provides a feasible approach for accurately identifying samples from consented NBS participants.
- 26 February 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (2) , 33
Health care providers’ perceptions of screening for risk of type 1 diabetes in newborns using genetic risk scores
To explore health care providers’ perceptions of using polygenic risk scores (PRS) to screen newborns for the risk of developing type 1 diabetes (T1D) prior to its implementation in Early Check, an expanded newborn screening program in North Carolina (NC), an online survey was conducted with pediatric providers in NC followed by interviews with a subset of providers who responded to the survey. Forty-eight providers completed the survey, and 14 participated in an interview. Participants identified improved health outcomes, provider decision-making, and parental decision-making as the primary potential benefits of screening for risk of T1D. Increased parental anxiety, insufficient provider knowledge, and out-of-pocket expenses for families were described as significant potential barriers. Participants requested tools for educating parents on screening and results, guidelines for follow-up and when to refer to a specialist, and access to a genetic counselor for questions. Participants were generally supportive of screening for T1D risk using PRS, though barriers need to be addressed to optimize the practice for widespread clinical use. This study fills a gap in the literature related to providers’ attitudes and perspectives on screening for T1D using PRS in newborns.
- 26 February 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (2) , 33
Health care providers’ perceptions of screening for risk of type 1 diabetes in newborns using genetic risk scores
To explore health care providers’ perceptions of using polygenic risk scores (PRS) to screen newborns for the risk of developing type 1 diabetes (T1D) prior to its implementation in Early Check, an expanded newborn screening program in North Carolina (NC), an online survey was conducted with pediatric providers in NC followed by interviews with a subset of providers who responded to the survey. Forty-eight providers completed the survey, and 14 participated in an interview. Participants identified improved health outcomes, provider decision-making, and parental decision-making as the primary potential benefits of screening for risk of T1D. Increased parental anxiety, insufficient provider knowledge, and out-of-pocket expenses for families were described as significant potential barriers. Participants requested tools for educating parents on screening and results, guidelines for follow-up and when to refer to a specialist, and access to a genetic counselor for questions. Participants were generally supportive of screening for T1D risk using PRS, though barriers need to be addressed to optimize the practice for widespread clinical use. This study fills a gap in the literature related to providers’ attitudes and perspectives on screening for T1D using PRS in newborns.
- 24 November 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (6) , e70141
Experiences of parents who receive a false‐positive CK ‐ MM screening for their newborn
Duchenne muscular dystrophy (DMD) is a rare inherited, X‐linked neuromuscular disorder that leads to a progressive decline in physical mobility, muscle atrophy, and premature death. Newborn screening (NBS) offers the potential for earlier diagnosis and earlier intervention, although NBS using the creatine kinase isoenzyme (CK‐MM) assay may detect conditions other than DMD and lead to initial false‐positive results. Early Check, a voluntary supplemental newborn screening study in North Carolina, screened 16,566 newborns for DMD over nearly 3 years. Parents and legal guardians of infants who received an initial false‐positive screen result for DMD ( n = 20) were interviewed about their experiences. Data were coded in NVivo using directed content analysis. Participants described feelings of stress, shock, and concern associated with receiving the initial positive screening result, and varying levels of stress and anxiety while waiting for confirmatory genomic panel testing during the follow‐up period. The study genetic counselor played a critical role in sharing the initial false‐positive results, answering parents'/guardians' questions, and informing them of factors other than DMD that can cause elevated CK‐MM levels. Despite the stressful experience of receiving a false‐positive result, parents/guardians found value in participating in Early Check, as it provided knowledge about their child's health and the opportunity for earlier intervention, if needed.
- 24 November 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (6) , e70141
Experiences of parents who receive a false‐positive CK ‐ MM screening for their newborn
Duchenne muscular dystrophy (DMD) is a rare inherited, X‐linked neuromuscular disorder that leads to a progressive decline in physical mobility, muscle atrophy, and premature death. Newborn screening (NBS) offers the potential for earlier diagnosis and earlier intervention, although NBS using the creatine kinase isoenzyme (CK‐MM) assay may detect conditions other than DMD and lead to initial false‐positive results. Early Check, a voluntary supplemental newborn screening study in North Carolina, screened 16,566 newborns for DMD over nearly 3 years. Parents and legal guardians of infants who received an initial false‐positive screen result for DMD ( n = 20) were interviewed about their experiences. Data were coded in NVivo using directed content analysis. Participants described feelings of stress, shock, and concern associated with receiving the initial positive screening result, and varying levels of stress and anxiety while waiting for confirmatory genomic panel testing during the follow‐up period. The study genetic counselor played a critical role in sharing the initial false‐positive results, answering parents'/guardians' questions, and informing them of factors other than DMD that can cause elevated CK‐MM levels. Despite the stressful experience of receiving a false‐positive result, parents/guardians found value in participating in Early Check, as it provided knowledge about their child's health and the opportunity for earlier intervention, if needed.
- 10 June 2025
- Published by Springer Nature in AIDS and Behavior
- p. 1-16
Development and Evaluation of Decision Partner: A Decision Aid for HIV Remission Clinical Trial Participation
HIV remission (or cure) clinical trials require potential participants to understand trial-related risks, approaches to minimize risks, potential benefits, procedures, and participation alternatives to make an informed decision. Decision aids (DAs) support preference-sensitive decisions. We report on the development and evaluation of a DA called Decision Partner, designed to support informed consent. We used an iterative, mixed-methods approach to develop and test Decision Partner. We conducted research and engagement activities among people living with HIV (PLWHIV), advocates, researchers, trialists, and clinicians which resulted in a product reflective of information required for informed choice. Among 20 PLWHIV, 90% rated that Decision Partner would be useful for decision-making. Decision conflict significantly decreased after using Decision Partner (37.3 to 16.8, p =.007) and knowledge significantly increased from pre to-post(z = -3.11, p <.01). Our findings indicated that Decision Partner holds promise to augment the informed consent process, in HIV remission trials.
- 10 June 2025
- Published by Springer Nature in AIDS and Behavior
- p. 1-16
Development and Evaluation of Decision Partner: A Decision Aid for HIV Remission Clinical Trial Participation
HIV remission (or cure) clinical trials require potential participants to understand trial-related risks, approaches to minimize risks, potential benefits, procedures, and participation alternatives to make an informed decision. Decision aids (DAs) support preference-sensitive decisions. We report on the development and evaluation of a DA called Decision Partner, designed to support informed consent. We used an iterative, mixed-methods approach to develop and test Decision Partner. We conducted research and engagement activities among people living with HIV (PLWHIV), advocates, researchers, trialists, and clinicians which resulted in a product reflective of information required for informed choice. Among 20 PLWHIV, 90% rated that Decision Partner would be useful for decision-making. Decision conflict significantly decreased after using Decision Partner (37.3 to 16.8, p =.007) and knowledge significantly increased from pre to-post(z = -3.11, p <.01). Our findings indicated that Decision Partner holds promise to augment the informed consent process, in HIV remission trials.
- 25 November 2024
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 56 (4) , 1473-1488
The Breastfeeding Experiences of Mother–Infant Dyads and the Effects of an FMR1 Mutation
This study examined the early breastfeeding experiences of mothers with an FMR1 premutation (FXPM) and their infants with and without fragile X syndrome (FXS) to identify early feeding needs and potential opportunities for intervention. Data collection occurred through a retrospective national survey that captured data on breastfeeding experiences and co-occurring conditions of mother and child. Participants were 246 mothers with an FXPM. Of their 384 infants, 287 had FXS and 97 were unaffected (i.e., they did not have FXS or an FXPM). Unaffected infants had a longer breastfeeding duration relative to infants with FXS, and infants of mothers who had postpartum depression (PPD). Additionally, infants who were reported to display aggressiveness towards others later in childhood had a shorter breastfeeding duration than those who did not go on to display aggression. Approximately 42% percent of mothers reported difficulties with breastfeeding infants with FXS compared to only 17% of unaffected infants. The most common reason for breastfeeding cessation for mothers of children with FXS was perceived difficulties in breastfeeding for the child (37%), whereas the most common reason for mothers of unaffected infants was a personal choice to stop (37%). This study provides preliminary evidence that infants with FXS show early phenotypes that make breastfeeding more difficult. Future research should investigate whether interventions for infants with FXS could improve breastfeeding outcomes.
- 25 November 2024
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 56 (4) , 1473-1488
The Breastfeeding Experiences of Mother–Infant Dyads and the Effects of an FMR1 Mutation
This study examined the early breastfeeding experiences of mothers with an FMR1 premutation (FXPM) and their infants with and without fragile X syndrome (FXS) to identify early feeding needs and potential opportunities for intervention. Data collection occurred through a retrospective national survey that captured data on breastfeeding experiences and co-occurring conditions of mother and child. Participants were 246 mothers with an FXPM. Of their 384 infants, 287 had FXS and 97 were unaffected (i.e., they did not have FXS or an FXPM). Unaffected infants had a longer breastfeeding duration relative to infants with FXS, and infants of mothers who had postpartum depression (PPD). Additionally, infants who were reported to display aggressiveness towards others later in childhood had a shorter breastfeeding duration than those who did not go on to display aggression. Approximately 42% percent of mothers reported difficulties with breastfeeding infants with FXS compared to only 17% of unaffected infants. The most common reason for breastfeeding cessation for mothers of children with FXS was perceived difficulties in breastfeeding for the child (37%), whereas the most common reason for mothers of unaffected infants was a personal choice to stop (37%). This study provides preliminary evidence that infants with FXS show early phenotypes that make breastfeeding more difficult. Future research should investigate whether interventions for infants with FXS could improve breastfeeding outcomes.
- Open Access
- 4 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0270169
Pilot protocol for the Parent and Infant Inter(X)action Intervention (PIXI) feasibility study
This paper provides the detailed protocol for a pilot study testing the feasibility, acceptability, and initial efficacy of a targeted two-phase, remotely delivered early intervention program for infants with neurogenetic conditions (NGC) and their caregivers. The Parent and Infant Inter(X)action Intervention (PIXI) is designed to support parents and infants with a NGC diagnosed in the first year of life. PIXI is implemented in two phases, with the first phase focusing on psychoeducation, parent support, and how to establish routines for supporting infant development. Phase II helps parents learn targeted skills to support their infant’s development as symptoms may begin to emerge. The proposed non-randomized feasibility pilot study will establish the feasibility of a year-long virtually implemented intervention program to support new parents of an infant diagnosed with an NGC.
- 4 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0270169
Open AccessPilot protocol for the Parent and Infant Inter(X)action Intervention (PIXI) feasibility study
This paper provides the detailed protocol for a pilot study testing the feasibility, acceptability, and initial efficacy of a targeted two-phase, remotely delivered early intervention program for infants with neurogenetic conditions (NGC) and their caregivers. The Parent and Infant Inter(X)action Intervention (PIXI) is designed to support parents and infants with a NGC diagnosed in the first year of life. PIXI is implemented in two phases, with the first phase focusing on psychoeducation, parent support, and how to establish routines for supporting infant development. Phase II helps parents learn targeted skills to support their infant’s development as symptoms may begin to emerge. The proposed non-randomized feasibility pilot study will establish the feasibility of a year-long virtually implemented intervention program to support new parents of an infant diagnosed with an NGC.
- Open Access
Pilot Protocol for the Parent and Infant Inter(X)action Intervention (PIXI) Feasibility Study
This paper provides the detailed protocol for a pilot study testing the feasibility, acceptability, and initial efficacy of a targeted two-phase, remotely delivered early intervention program for infants with neurogenetic conditions (NGC) and their caregivers. The Parent and Infant Inter(X)action Intervention (PIXI) is designed to support parents and infants with an NGC diagnosed in the first year of life. PIXI is implemented in two phases, with the first phase focusing on psychoeducation, parent support, and how to establish routines for supporting infant development. Phase II helps parents learn targeted skills to support their infant’s development as symptoms may begin to emerge. The proposed case series will establish the feasibility of a year-long virtually implemented intervention program to support new parents of an infant diagnosed with an NGC.
Open AccessPilot Protocol for the Parent and Infant Inter(X)action Intervention (PIXI) Feasibility Study
This paper provides the detailed protocol for a pilot study testing the feasibility, acceptability, and initial efficacy of a targeted two-phase, remotely delivered early intervention program for infants with neurogenetic conditions (NGC) and their caregivers. The Parent and Infant Inter(X)action Intervention (PIXI) is designed to support parents and infants with an NGC diagnosed in the first year of life. PIXI is implemented in two phases, with the first phase focusing on psychoeducation, parent support, and how to establish routines for supporting infant development. Phase II helps parents learn targeted skills to support their infant’s development as symptoms may begin to emerge. The proposed case series will establish the feasibility of a year-long virtually implemented intervention program to support new parents of an infant diagnosed with an NGC.